Dicerna Pharmaceuticals (DRNA +1.6%) and collaboration partner Alexion Pharmaceuticals (ALXN +0.8%) announce that the latter has exercised its option for exclusive rights to two additional GalXC RNAi targets within the complement pathway, increasing the number of programs to four.
Alexion will pay Dicerna $20M for the two licenses.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.